A New Prognostic Score for Elderly Patients with Diffuse Large
B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of
Blood Monocyte and Lymphocyte Counts Is Absent

J 2014

A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent

PROCHÁZKA, Vít, Robert PYTLÍK, Andrea JANÍKOVÁ, David BELADA, David ŠÁLEK et. al.

Základní údaje

Originální název

A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent

Autoři

PROCHÁZKA, Vít (203 Česká republika), Robert PYTLÍK (203 Česká republika), Andrea JANÍKOVÁ (203 Česká republika, garant, domácí), David BELADA (203 Česká republika), David ŠÁLEK (203 Česká republika, domácí), Tomáš PAPAJÍK (203 Česká republika), Vít CAMPR (203 Česká republika), Tomáš FÜRST (203 Česká republika), Jana FURSTOVA (203 Česká republika) a Marek TRNĚNÝ (203 Česká republika)

Vydání

Plos one, San Francisco, Public Library Science, 2014, 1932-6203

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.234

Kód RIV

RIV/00216224:14110/14:00080009

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1371/journal.pone.0102594

UT WoS

000341354800028

Klíčová slova anglicky

NON-HODGKINS-LYMPHOMA; ABSOLUTE LYMPHOCYTE; PATIENTS OLDER; RITUXIMAB ERA; TRIAL; CHEMOTHERAPY; SURVIVAL; SUBTYPE; MARKER; IPI

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 4. 2015 11:46, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Background: Absolute lymphocyte count (ALC) and absolute monocyte count (AMC) have been documented as independent predictors of survival in patients with newly diagnosed Diffuse Large B-cell Lymphoma (DLBCL). Analysis of the prognostic impact of ALC and AMC in the context of International Prognostic Index (IPI) and other significant variables in elderly population treated in the R-CHOP regime has not been carried out yet. Methodology/Principal Findings: In this retrospective study, a cohort of 443 newly diagnosed DLBCL patients with age >= 60 was analyzed. All patients were treated with the R-CHOP therapy. An extensive statistical analysis was performed to identify risk factors of 3-year overall survival (OS). In multivariate analysis, only three predictors proved significant: Eastern Cooperative Oncology Group performance status (ECOG), age and bulky disease presence. These predictors were dichotomized (ECOG >= 1, age >= 70, bulk >= 7.5) to create a novel four-level score. This score predicted 3-year OS of 94.0%, 77.4%, 62.7% and 35.4% in the low-, low-intermediate, high-intermediate and high-risk groups, respectively (P<0.001). Further, a three-level score was tested which stratifies the population better (3-year OS: 91.9%, 67.2%, 36.2% in the low, intermediate and high-risk groups, respectively) but is more difficult to interpret. Both the 3- and 4-level scores were compared to standard scoring systems and, in our population, were shown to be superior in terms of patients risk stratification with respect to 3-year OS prediction. The results were successfully validated on an independent cohort of 162 patients of similar group characteristics. Conclusions: The prognostic role of baseline ALC, AMC or their ratio (LMR) was not confirmed in the multivariate context in elderly population with DLBCL treated with R-CHOP. The newly proposed age-specific index stratifies the elderly population into risk groups more precisely than the conventional IPI and its existing variants.

Citovat

PROCHÁZKA, Vít, Robert PYTLÍK, Andrea JANÍKOVÁ, David BELADA, David ŠÁLEK, Tomáš PAPAJÍK, Vít CAMPR, Tomáš FÜRST, Jana FURSTOVA a Marek TRNĚNÝ. A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent. Plos one. San Francisco: Public Library Science, 2014, roč. 9, č. 7, s. 1-10. ISSN 1932-6203. Dostupné z: https://dx.doi.org/10.1371/journal.pone.0102594.

@article{1297252,
   author = {Procházka, Vít and Pytlík, Robert and Janíková, Andrea and Belada, David and Šálek, David and Papajík, Tomáš and Campr, Vít and Fürst, Tomáš and Furstova, Jana and Trněný, Marek},
   article_location = {San Francisco},
   article_number = {7},
   doi = {http://dx.doi.org/10.1371/journal.pone.0102594},
   keywords = {NON-HODGKINS-LYMPHOMA; ABSOLUTE LYMPHOCYTE; PATIENTS OLDER; RITUXIMAB ERA; TRIAL; CHEMOTHERAPY; SURVIVAL; SUBTYPE; MARKER; IPI},
   language = {eng},
   issn = {1932-6203},
   journal = {Plos one},
   title = {A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent},
   volume = {9},
   year = {2014}
}

TY  - JOUR
ID  - 1297252
AU  - Procházka, Vít - Pytlík, Robert - Janíková, Andrea - Belada, David - Šálek, David - Papajík, Tomáš - Campr, Vít - Fürst, Tomáš - Furstova, Jana - Trněný, Marek
PY  - 2014
TI  - A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent
JF  - Plos one
VL  - 9
IS  - 7
SP  - 1-10
EP  - 1-10
PB  - Public Library Science
SN  - 19326203
KW  - NON-HODGKINS-LYMPHOMA
KW  - ABSOLUTE LYMPHOCYTE
KW  - PATIENTS OLDER
KW  - RITUXIMAB ERA
KW  - TRIAL
KW  - CHEMOTHERAPY
KW  - SURVIVAL
KW  - SUBTYPE
KW  - MARKER
KW  - IPI
N2  - Background: Absolute lymphocyte count (ALC) and absolute monocyte count (AMC) have been documented as independent predictors of survival in patients with newly diagnosed Diffuse Large B-cell Lymphoma (DLBCL). Analysis of the prognostic impact of ALC and AMC in the context of International Prognostic Index (IPI) and other significant variables in elderly population treated in the R-CHOP regime has not been carried out yet. Methodology/Principal Findings: In this retrospective study, a cohort of 443 newly diagnosed DLBCL patients with age >= 60 was analyzed. All patients were treated with the R-CHOP therapy. An extensive statistical analysis was performed to identify risk factors of 3-year overall survival (OS). In multivariate analysis, only three predictors proved significant: Eastern Cooperative Oncology Group performance status (ECOG), age and bulky disease presence. These predictors were dichotomized (ECOG >= 1, age >= 70, bulk >= 7.5) to create a novel four-level score. This score predicted 3-year OS of 94.0%, 77.4%, 62.7% and 35.4% in the low-, low-intermediate, high-intermediate and high-risk groups, respectively (P<0.001). Further, a three-level score was tested which stratifies the population better (3-year OS: 91.9%, 67.2%, 36.2% in the low, intermediate and high-risk groups, respectively) but is more difficult to interpret. Both the 3- and 4-level scores were compared to standard scoring systems and, in our population, were shown to be superior in terms of patients risk stratification with respect to 3-year OS prediction. The results were successfully validated on an independent cohort of 162 patients of similar group characteristics. Conclusions: The prognostic role of baseline ALC, AMC or their ratio (LMR) was not confirmed in the multivariate context in elderly population with DLBCL treated with R-CHOP. The newly proposed age-specific index stratifies the elderly population into risk groups more precisely than the conventional IPI and its existing variants.
ER  -

PROCHÁZKA, Vít, Robert PYTLÍK, Andrea JANÍKOVÁ, David BELADA, David ŠÁLEK, Tomáš PAPAJÍK, Vít CAMPR, Tomáš FÜRST, Jana FURSTOVA a Marek TRNĚNÝ. A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent. \textit{Plos one}. San Francisco: Public Library Science, 2014, roč.~9, č.~7, s.~1-10. ISSN~1932-6203. Dostupné z: https://dx.doi.org/10.1371/journal.pone.0102594.

Podrobný výpis o publikaci